Researchers at Nano Life Science Institute (WPI-NanoLSI) and the Cancer Research Institute at Kanazawa University have uncovered how targeted lung cancer drugs alter the shape and behavior of a key ...
Sequential therapy strategies in oncogene-driven NSCLC. This figure illustrates a proposed therapeutic decision-making pathway for patients with NSCLC who develop acquired resistance after initial ...
Good morning, and welcome to Nuvalent's conference call. [Operator Instructions] Please be advised that this call is being recorded at the company's request. I would now like to turn the call over to ...
Nuvalent has reported phase 1/2 lung cancer data, teeing the biotech up to talk to the FDA about an approval filing that could establish its neladalkib as a challenger to Pfizer’s Lorbrena. The ALKOVE ...
Adults in England and Wales with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) will soon have access to a new first-line treatment. The National Institute for ...
Researchers at Children's Hospital of Philadelphia (CHOP) unveiled a novel antibody-drug conjugate (ADC) that shows striking efficacy against cancers that express the anaplastic lymphoma kinase (ALK) ...
A new study suggests a gene mutation could have a protective effect against Alzheimer's. The research looked specifically at blood stem cells, which live in the bone marrow and make different types of ...
BURBANK, Calif. (KABC) -- Cancer is not a welcome diagnosis, but breakthroughs in genetic sequencing and immunotherapy are making some cancers easier to treat than others. A local father and ...
WEDNESDAY, June 25, 2025 (HealthDay News) -- For women with breast cancer (BC), BRCA mutations are associated with increased risk of developing breast implant–associated anaplastic large cell lymphoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results